WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Ziconotide

Governed registry record

153 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. A Chemoenzymatic Approach To Produce a Cyclic Analogue of the Analgesic Drug MVIIA (Ziconotide)

    DOI: 10.1002/ange.202302812

    Source identity and connection checked by Codex (AI).

  2. A Simple Approach to Assign Disulfide Connectivity for Ziconotide via Partial Reduction Without Alkylation.

    DOI: 10.1002/rcm.10026PMID: 40084697

    Source identity and connection checked by Codex (AI).

  3. Determination of related substances in disulfide-rich peptide ziconotide by establishing tandem mass spectrometry methods.

    DOI: 10.1016/j.jpha.2024.101037PMID: 39386004

    Source identity and connection checked by Codex (AI).

  4. Efficacy and safety of the Ca<sub>v</sub>2.2 blocker Ziconotide in pain: a meta-analysis and systematic review.

    DOI: 10.1097/pr9.0000000000001363PMID: 41255849

    Source identity and connection checked by Codex (AI).

  5. Functional crosstalk between neuropeptide FF system and N-type voltage-gated calcium channels in ziconotide-mediated antinociception in mice.

    DOI: 10.1007/s00213-026-07053-4PMID: 41910723

    Source identity and connection checked by Codex (AI).

  6. ID:15841 A Case of Prolonged Psychosis With Intrathecal Ziconotide

    DOI: 10.1016/j.neurom.2022.02.146

    Source identity and connection checked by Codex (AI).

  7. Recurrent Ziconotide-Associated Delirium and Psychosis: A Case Report.

    DOI: 10.1097/jcp.0000000000002021PMID: 40511848

    Source identity and connection checked by Codex (AI).

  8. Scalable Ligand-Receptor Binding Affinity Landscape: A Case Study with Ziconotide and Ca<sub>V</sub>2.2

    DOI: 10.20944/preprints202409.0877.v1

    Source identity and connection checked by Codex (AI).

  9. Ziconotide ( ω‐conotoxin MVIIA )—Efficient solid‐phase synthesis of a linear precursor peptide and its strategic native folding

    DOI: 10.1002/pep2.24223

    Source identity and connection checked by Codex (AI).

  10. Ziconotide and pain in multiple sclerosis: a case report

    DOI: 10.22541/au.176521176.64921719/v1

    Source identity and connection checked by Codex (AI).

  11. Ziconotide as an Opioid Rescue: Economic, Clinical, and Subgroup Considerations [Letter].

    DOI: 10.2147/jpr.s571927PMID: 41229894

    Source identity and connection checked by Codex (AI).

  12. Intrathecal Ziconotide Long-Term Management in Chronic Postamputation Pain.

    2026

    DOI: 10.1155/cria/9977830PMID: 42548796

  13. Real-Life Data on Ziconotide-Based Intrathecal Therapy in Patients With Cancer Pain: Interim Analysis of the Observational Practice in Clinics Registry.

    2026

    DOI: 10.1016/j.neurom.2026.04.006PMID: 42189020

  14. Can Ziconotide Be Used to Replace Opioids? Exploratory Clinical Experience in 5 Patients Treated in the Pain Unit.

    2025

    DOI: 10.2147/jpr.s528946PMID: 40985013

  15. Dilution of Ziconotide for Intrathecal Trial: The Effect of Dilution on the Incidence of Side Effects and Pain Relief: A Single-center Retrospective Case-control Study.

    2025

    DOI: 10.36076/ppj.2025.28.147PMID: 40168566

  16. A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review.

    2024

    DOI: 10.3390/jcm13061644PMID: 38541869

  17. A comprehensive review on ziconotide.

    2024

    DOI: 10.1016/j.heliyon.2024.e31105PMID: 38779019

  18. Intrathecal Ziconotide Infusion Therapy for Oncologic Refractory Neuropathic Pain: Case Report With High-Dose Intraventricular Ziconotide After 15 Years of Treatment.

    2024

    DOI: 10.1016/j.neurom.2024.06.495PMID: 39078347

  19. Intrathecal ziconotide for the treatment of chronic pain: a collection of clinical experiences and literature review.

    2024

    DOI: 10.26355/eurrev_202408_36640PMID: 39194195

  20. Physicochemical Stability Study of the Morphine-Bupivacaine-Ziconotide Association.

    2024

    DOI: 10.1016/j.neurom.2023.11.009PMID: 38300172

  21. SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions.

    2024

    DOI: 10.1186/s13063-024-08387-0PMID: 39244617

  22. Ziconotide and psychosis: from a case report to a scoping review.

    2024

    DOI: 10.3389/fnmol.2024.1412855PMID: 39479264

  23. A Chemoenzymatic Approach To Produce a Cyclic Analogue of the Analgesic Drug MVIIA (Ziconotide).

    2023

    DOI: 10.1002/anie.202302812PMID: 37148162

  24. Long-Term Follow-Up (>11 Years) on Successful Pregnancies With Ziconotide Monotherapy for Arachnoiditis-Related Chronic Pain.

    2023

    DOI: 10.1016/j.neurom.2022.05.008PMID: 37548188

  25. Microneedle-mediated delivery of Ziconotide-loaded liposomes fused with exosomes for analgesia.

    2023

    DOI: 10.1016/j.jconrel.2023.03.007PMID: 36898532

  26. Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration.

    2023

    DOI: 10.1016/j.neurom.2021.10.002PMID: 35088750

  27. Ziconotide for the Management of Cancer Pain: A Budget Impact Analysis.

    2023

    DOI: 10.1016/j.neurom.2022.08.458PMID: 36202713

  28. Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines.

    2022

    DOI: 10.7759/cureus.23714PMID: 35505713

  29. Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing.

    2021

    DOI: 10.1016/j.wneu.2020.10.079PMID: 33096281

  30. Intrathecal pain management with ziconotide: Time for consensus?

    2021

    DOI: 10.1002/brb3.2055PMID: 33690987

  31. Short-Term Outcomes of a High-Volume, Low-Concentration Bolus Starting Dose Technique With Ziconotide: A Case Series.

    2021

    DOI: 10.1111/ner.13475PMID: 34252245

  32. Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes.

    2021

    DOI: 10.1111/ner.13289PMID: 33095956

  33. Structure of human Ca<sub>v</sub>2.2 channel blocked by the painkiller ziconotide.

    2021

    DOI: 10.1038/s41586-021-03699-6PMID: 34234349

  34. [What became of Prialt®? : Observational study on the use of ziconotide in the treatment of chronic pain].

    2021

    DOI: 10.1007/s00482-021-00531-yPMID: 33507370

  35. Antidepressant-like and memory-enhancing effects of the N-type calcium channel blocker ziconotide in rats.

    2020

    DOI: 10.1016/j.bbr.2020.112647PMID: 32428635

  36. Effectiveness and Safety of Intrathecal Ziconotide: Final Results of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).

    2020

    DOI: 10.1093/pm/pnaa115PMID: 32472137

  37. Intracerebroventricular administration of N-type calcium channel blocker ziconotide displays anticonvulsant, anxiolytic, and sedative effects in rats: A preclinical and pilot study.

    2020

    DOI: 10.1016/j.yebeh.2020.107251PMID: 32593873

  38. Study of Physicochemical Stability of Ziconotide in Medication Cassette Reservoir.

    2020

    DOI: 10.1111/ner.13218PMID: 32743885

  39. Ziconotide for Management of Cancer Pain Refractory to Pharmacotherapy: An Update.

    2020

    DOI: 10.1093/pm/pnaa251PMID: 32940675

  40. Ziconotide-Induced Oro-lingual Dyskinesia: 3 Cases.

    2020

    DOI: 10.5334/tohm.431PMID: 33101763

  41. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.

    2019

    DOI: 10.1093/pm/pny132PMID: 30137539

  42. Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report.

    2019

    DOI: 10.1213/xaa.0000000000000978PMID: 31260413

  43. Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways.

    2019

    DOI: 10.1016/j.jprot.2018.05.009PMID: 29777871

  44. Ziconotide for spinal cord injury-related pain.

    2019

    DOI: 10.1002/ejp.1445PMID: 31233255

  45. Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice.

    2018

    DOI: 10.1002/ejp.1229PMID: 29635804

  46. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).

    2018

    DOI: 10.1111/papr.12599PMID: 28449352

  47. Ziconotide-induced psychosis: A case report and literature review.

    2018

    DOI: 10.9740/mhc.2018.09.242PMID: 30206508

  48. Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.

    2017

    PMID: 28719378

  49. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report.

    2017

    DOI: 10.1213/xaa.0000000000000432PMID: 28195861

  50. The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain.

    2017

    DOI: 10.2174/1570159x14666160210142339PMID: 26861471

  51. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.

    2017

    DOI: 10.1111/ner.12486PMID: 27492135

  52. Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials.

    2017

    DOI: 10.2174/1570159x14666160210142056PMID: 26861472

  53. Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.

    2016

    DOI: 10.1016/j.jconrel.2015.12.044PMID: 26732557

  54. Does pain relief influence recovery of consciousness? A case report of a patient treated with ziconotide.

    2016

    PMID: 25491316

  55. Intracerebroventricular Pain Treatment with Analgesic Mixtures including Ziconotide for Intractable Pain.

    2016

    PMID: 27454282

  56. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.

    2016

    DOI: 10.1111/ner.12392PMID: 26856969

  57. Ziconotide intrathecal delivery as treatment for secondary therapeutic failure of motor cortex stimulation after 6 years.

    2016

    DOI: 10.1016/j.neuchi.2016.06.007PMID: 27771111

  58. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.

    2015

    DOI: 10.1111/papr.12273PMID: 25565390

  59. Aseptic arachnoiditis in a patient treated with intrathecal morphine infusion: symptom resolution on switch to ziconotide.

    2015

    DOI: 10.1111/ner.12201PMID: 24945709

  60. Dual Effect of Ziconotide in Primary Erythromelalgia.

    2015

    DOI: 10.1155/2015/592170PMID: 26609309

  61. Influence of pH and temperature on ziconotide stability in intrathecal analgesic admixtures in implantable pumps and syringes.

    2015

    DOI: 10.1016/j.ijpharm.2015.04.041PMID: 25891257

  62. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.

    2015

    DOI: 10.1111/ner.12274PMID: 25708382

  63. Intrathecal Ziconotide and Morphine for Pain Relief: A Case Series of Eight Patients with Refractory Cancer Pain, Including Five Cases of Neuropathic Pain.

    2015

    DOI: 10.1007/s40120-015-0035-zPMID: 26563119

  64. Rationale for Prospective Assays of Intrathecal Mixtures Including Morphine, Ropivacaine and Ziconotide: Prevention of Adverse Events and Feasibility in Clinical Practice.

    2015

    DOI: 10.36076/ppj.2015/18/349PMID: 26218938

  65. Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers.

    2015

    DOI: 10.1038/srep12497PMID: 26234920

  66. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.

    2015

    DOI: 10.1111/pme.12666PMID: 25645109

  67. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up.

    2015

    DOI: 10.1111/ner.12270PMID: 25655991

  68. Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment.

    2015

    DOI: 10.1111/ner.12293PMID: 25879804

  69. Ziconotide-induced psychosis: a case report.

    2015

    DOI: 10.1016/j.genhosppsych.2014.10.001PMID: 25459190

  70. Dyskinesia caused by ziconotide-baclofen combination in an adolescent affected by cerebral palsy.

    2014

    DOI: 10.1097/aap.0000000000000054PMID: 24513956

  71. In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps.

    2014

    DOI: 10.1111/ner.12142PMID: 24512055

  72. Acute cardiovascular toxicity of low-dose intrathecal ziconotide.

    2013

    DOI: 10.1111/pme.12196PMID: 23855951

  73. Administering ziconotide and monitoring patients treated with ziconotide: expert opinions.

    2013

    DOI: 10.1016/j.pmn.2011.05.004PMID: 23972874

  74. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.

    2013

    DOI: 10.1111/ner.12003PMID: 23205907

  75. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.

    2013

    DOI: 10.1007/s40263-013-0107-5PMID: 23999971

  76. Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel CaV2.2 pre-mRNA.

    2013

    DOI: 10.1186/1744-8069-9-67PMID: 24369063

  77. Ziconotide: a clinical update and pharmacologic review.

    2013

    DOI: 10.1517/14656566.2013.784269PMID: 23537340

  78. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.

    2012

    DOI: 10.1016/j.pain.2011.10.002PMID: 22082570

  79. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog.

    2012

    DOI: 10.1111/j.1525-1403.2012.00479.xPMID: 22748108

  80. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.

    2012

    DOI: 10.36076/ppj.2012/15/395PMID: 22996851

  81. Can ziconotide as a N-type voltage-sensitive calcium channel blocker open a new mode for treatment of autism? A hypothesis.

    2011

    PMID: 21206454

  82. Increased risk of suicide under intrathecal ziconotide treatment? - a warning.

    2011

    DOI: 10.1016/j.pain.2010.10.007PMID: 21041028

  83. Italian registry on long-term intrathecal ziconotide treatment.

    2011

    DOI: 10.36076/ppj.2011/14/15PMID: 21267038

  84. Psychiatric predisposition to autonomic and abnormal perception side-effects of ziconotide: a case series study.

    2011

    DOI: 10.1111/j.1525-1403.2011.00334.xPMID: 21992243

  85. Trigeminal neuralgia relief with intrathecal ziconotide.

    2011

    DOI: 10.1097/ajp.0b013e3181fb22f4PMID: 21494183

  86. Ziconotide: A rapid detoxification protocol for the conversion from intrathecal morphine--the Raffaeli Detoxification Model.

    2011

    DOI: 10.5055/jom.2011.0045PMID: 21434581

  87. [Experience in treatment of patients with neuropathic facial pain using ziconotide].

    2011

    DOI: 10.1007/s00482-011-1080-xPMID: 21818721

  88. [Neuropsychiatric side effects of intrathecal ziconotide].

    2011

    DOI: 10.33588/rn.5201.2010475PMID: 21246497

  89. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.

    2010

    DOI: 10.1111/j.1526-4637.2009.00741.xPMID: 20002322

  90. Case report: successful treatment of a patient with trigeminal neuropathy using ziconotide.

    2010

    DOI: 10.1213/ane.0b013e3181cfc307PMID: 20142352

  91. Considerations and methodology for trialing ziconotide.

    2010

    DOI: 10.36076/ppj.2010/13/23PMID: 20119460

  92. Ziconotide combination intrathecal therapy: rationale and evidence.

    2010

    DOI: 10.1097/ajp.0b013e3181e017dfPMID: 20639730

  93. Ziconotide for treatment of severe chronic pain.

    2010

    DOI: 10.1016/s0140-6736(10)60354-6PMID: 20413151

  94. [Recommendations for the management of chronic pain by intrathecal ziconotide].

    2010

    PMID: 21595155

  95. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK.

    2009

    DOI: 10.1185/03007990903090849PMID: 19563256

  96. Intrathecal therapy: what has changed with the introduction of ziconotide.

    2009

    DOI: 10.1111/j.1533-2500.2009.00308.xPMID: 19740270

  97. Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports.

    2009

    PMID: 19156022

  98. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.

    2009

    PMID: 19668287

  99. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.

    2009

    DOI: 10.1111/j.1533-2500.2009.00289.xPMID: 19500276

  100. Intrathecal ziconotide for neuropathic pain: a review.

    2009

    DOI: 10.1111/j.1533-2500.2009.00303.xPMID: 19682321

  101. Long-term intrathecal ziconotide for chronic pain: an open-label study.

    2009

    DOI: 10.1016/j.jpainsymman.2008.02.016PMID: 18715748

  102. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain.

    2009

    DOI: 10.2147/tcrm.s4438PMID: 19707262

  103. Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label Study.

    2008

    DOI: 10.1111/j.1525-1403.2007.00141.xPMID: 22150990

  104. Dilution and compounding of ziconotide for intrathecal administration.

    2008

    PMID: 23969707

  105. Intrathecal therapy with ziconotide: clinical experience and considerations on its use.

    2008

    PMID: 19034250

  106. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial.

    2008

    DOI: 10.1213/ane.0b013e3181606fadPMID: 18227325

  107. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.

    2008

    DOI: 10.1111/j.1526-4637.2007.00356.xPMID: 18366508

  108. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.

    2008

    DOI: 10.1111/j.1526-4637.2007.00355.xPMID: 18366507

  109. Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration.

    2008

    DOI: 10.1016/j.jpainsymman.2008.01.007PMID: 18538975

  110. Using ziconotide for intrathecal infusions.

    2008

    DOI: 10.1097/01.nurse.0000342012.07225.e4PMID: 19033968

  111. Ziconotide: an update and review.

    2008

    DOI: 10.1517/14656566.9.9.1575PMID: 18518786

  112. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration.

    2007

    DOI: 10.1111/j.1525-1403.2007.00130.xPMID: 22150946

  113. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.

    2007

    DOI: 10.1080/10915810701582970PMID: 17963128

  114. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report.

    2007

    DOI: 10.1038/sj.sc.3102027PMID: 17310258

  115. Ziconotide: a review of its pharmacology and use in the treatment of pain.

    2007

    DOI: 10.2147/nedt.2007.3.1.69PMID: 19300539

  116. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].

    2007

    DOI: 10.33588/rn.4511.2007266PMID: 18050098

  117. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.

    2006

    DOI: 10.1016/j.jpainsymman.2005.10.003PMID: 16716870

  118. An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide.

    2006

    DOI: 10.1016/j.jpainsymman.2006.08.002PMID: 17157748

  119. Intrathecal ziconotide for refractory chronic pain.

    2006

    DOI: 10.1345/aph.1g584PMID: 16849624

  120. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial.

    2006

    DOI: 10.1111/j.1525-1403.2006.00055.xPMID: 22151630

  121. Treatment challenges and complications with ziconotide monotherapy in established pump patients.

    2006

    PMID: 16703976

  122. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.

    2006

    DOI: 10.1592/phco.26.3.395PMID: 16503720

  123. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.

    2006

    DOI: 10.5414/cpp44478PMID: 17063978

  124. Ziconotide.

    2006

    PMID: 37247359

  125. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.

    2006

    DOI: 10.1586/14737175.6.10.1423PMID: 17078783

  126. Ziconotide: a new option for refractory pain.

    2006

    DOI: 10.1358/dot.2006.42.6.973534PMID: 16845440

  127. [New medications; ziconotide].

    2006

    PMID: 17131701

  128. Elan: ziconotide review focused on off-label uses.

    2005

    DOI: 10.1177/104990910502200602PMID: 16323709

  129. New drugs: tigecycline, ziconotide, and clofarabine.

    2005

    DOI: 10.1331/1544345055001238PMID: 16295652

  130. Ziconotide (Prialt) for chronic pain.

    2005

    PMID: 16331245

  131. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.

    2005

    DOI: 10.1592/phco.2005.25.8.1084PMID: 16207099

  132. Ziconotide: can we use it in palliative care?

    2005

    DOI: 10.1177/104990910502200510PMID: 16225359

  133. Intrathecal ziconotide for chronic pain.

    2004

    DOI: 10.1001/jama.292.14.1681-bPMID: 15479926

  134. Intrathecal ziconotide for refractory pain.

    2004

    DOI: 10.1517/13543784.13.7.875PMID: 15212625

  135. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.

    2004

    DOI: 10.1001/jama.291.1.63PMID: 14709577

  136. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.

    2004

    DOI: 10.2174/0929867043363884PMID: 15578997

  137. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients.

    2003

    DOI: 10.1177/0091270003043006008PMID: 12817525

  138. Intractable delirium associated with ziconotide successfully treated with electroconvulsive therapy.

    2002

    DOI: 10.1176/appi.psy.43.1.63PMID: 11927761

  139. Long-term intrathecal ziconotide therapy: a case study and discussion.

    2001

    DOI: 10.1046/j.1525-1403.2001.00121.xPMID: 22151657

  140. Ziconotide (Elan Pharmaceuticals).

    2001

    PMID: 16025393

  141. Adverse effects associated with the intrathecal administration of ziconotide.

    2000

    DOI: 10.1016/s0304-3959(99)00254-7PMID: 10692631

  142. An evaluation of intrathecal ziconotide for the treatment of chronic pain.

    2000

    DOI: 10.1517/13543784.9.10.2403PMID: 11060815

  143. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion.

    2000

    DOI: 10.1016/s0196-9781(00)00175-3PMID: 10822104

  144. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.

    2000

    DOI: 10.1016/s0304-3959(99)00197-9PMID: 10666519

  145. Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose-response and time-window profiles for administration of the calcium channel blocker Ziconotide in experimental brain injury.

    2000

    DOI: 10.3171/jns.2000.93.5.0829PMID: 11059665

  146. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.

    2000

    DOI: 10.1016/s0304-3959(99)00214-6PMID: 10666532

  147. Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats.

    2000

    DOI: 10.3171/jns.2000.93.5.0821PMID: 11059664

  148. Ziconotide for the treatment of severe spasticity after spinal cord injury.

    2000

    DOI: 10.1016/s0304-3959(99)00255-9PMID: 10692630

  149. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.

    2000

    DOI: 10.1016/s1098-7339(00)90010-5PMID: 10834782

  150. Effects of an N-type calcium channel antagonist (SNX 111; Ziconotide) on calcium-45 accumulation following fluid-percussion injury.

    1999

    DOI: 10.1089/neu.1999.16.879PMID: 10547097

  151. The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia.

    1999

    DOI: 10.1016/s0741-5214(99)70145-xPMID: 10436454

  152. USAN Council. List No.421. New names. Ziconotide.

    1999

    PMID: 10610271

  153. Ziconotide. CI 1009, SNX 111.

    1999

    DOI: 10.2165/00126839-199901010-00019PMID: 10565986